ESR1 and breast carcinoma: Furthermore, bortezomib, a specific 26S proteasome inhibitor in phase II clinical trial used to treat endocrine-refractory, metastatic ER+ breast cancer in combination with fulvestrant[76] suppressed growth driven by ESR1-e6>YAP1.